Kaliebe T, Schroder U, Schmitz T, Maciejewski W, Gummer M, Breit R; International Conference on AIDS.
Int Conf AIDS. 1993 Jun 6-11; 9: 396 (abstract no. PO-B12-1566).
Dept. of Dermatology, City Hospital Schwabing, Munich, Germany.
In opposition to the decreasing prevalence among all risk groups, epidemic Kaposi's sarcoma (EKS) is still the most frequent AIDS-associated malignancy. Current therapeutical approaches include various systemic and local treatment modalities. Local therapy plays an important role in circumscribed lesions and also in advanced cases for systemic therapy is often limited by intolerance to drugs, concomitant bone marrow dysfunction and severe T-helper cell depletion. Radiation therapy is well known as the cornerstone of local therapy. Out of 110 EKS-patients treated between 1990 and 1992 a total of 772 KS lesions in 69 patients were irradiated using a Siemens Dermopan II soft X-ray machine (in most cases tube potential was 43 kV, TSD 15 cm, HVD 5.5 mm). To achieve clinically and histologically complete or partial response according to the WHO-criteria in more than 90 percent of the tumors we recommend a radiation schedule with a total dose of 3000 cGy with daily fractions of 300 cGy especially in the face to avoid striking hyperpigmentation. Single fractions of 200 cGy should be given to larger lesions (e.g. diameter > 2 cm) on the penis and the soles to avoid painful edema. On the trunk and the extremities 6 fractions of 500 cGy can be administered alternatively. Severe side effects like oozing, ulceration or necrosis have not been recorded. Cases on various sites will be demonstrated.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Humans
- Hyperpigmentation
- Male
- Pain
- Palliative Care
- Photochemotherapy
- Prevalence
- Remission Induction
- Sarcoma, Kaposi
- X-Ray Therapy
- drug therapy
- radiotherapy
- therapy
Other ID:
UI: 102204507
From Meeting Abstracts